1[5]Murasaki M. Overview of serotonin 1A receptor selective agents in anxiety disorders - the developmental situation in Japan. Int Rev Psychiatry, 1995, 7:105～113
2[6]Murasaki M, Miura S. Future of 5-HT1A receptor agonists (aryl-piperazine derivatives). Prog Neuro-Psychopharmacol &Biol Psychiatry, 1992, 16:833～845
3[7]Matsumoto M, Yoshioka M. Possible involvment of serotonin receptors in anxiety disorders. Nippon Yakurigahu Zasshi, 2000,115 (Suppl.): S39～S44
4[8]Shimizu H, Kariai N, Hirose A, et al. Interaction of SM-3997with serotonin receptors in rat brain. Jpn J Pharmacol, 1998,46:311～314
5[9]Shimizu H, Tatsuno T, Tanaka H, et al. Serotonergic mechanism in anxiolytic effect of tandospirone in the vogel conflict test.Jpn J Pharmacol, 1992, 59:105～122
6[10]Barradell LB, Fitton A. Tandospirone. CNC Drug, 1996, 5:147～153
7[11]Lucki I. Behavioral studies of serotonin receptor agonists as antidepressant drug. J Clin Psychiatry, 1991, 52 (Suppl.): S24～S31
8[13]Sumiyoshi T, Matsui M, Yamashita I, et al. The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Bio Psychiatry, 2001, 49:861～868
9[14]Tamai H, Komaki G, Kubota S, et al. The clinical efficacy of a 5-HT1A agonists, SM-1997, in the treatment of bulimia. IntJ Obesity, 1990, 14:289～292
10[15]Yoshida K, Sugita T, Higuchi H, et al. Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms. Eur Psychiatry, 1998, 13 (8): 421～422
9Hiroto Miwa,A.Nagahara,K.Tominaga.et al.Efficacy of the 5～HTIA Agonist Tandospirone Citrate in Improving Symptoms of Patients With Functional Dyspepsia:A Randomized Controlled Trial.Am J Gastroenterol[J].Nov,2009,104(11):2779～2787.
